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Background: Studies of patients meeting clinical and
pathologic criteria for Alzheimer disease (AD) have not
consistently found associations between the presence of
Lewy bodies (LBs) at postmortem examination and a
higher frequency during life of the clinical features of de-
mentia with LBs.
Objective: To evaluate the clinical correlates of LBs in
patients with AD.
Design and Methods: Fifty-one patients were diag-
nosed as having probable AD during life and met patho-
logic criteria for AD. Semiquantitative ratings for LBs were
obtained in 4 brain regions: substantia nigra, cingulate,
insular cortex, and hippocampus. The patients had been
followed up semiannually for up to 9.9 years before death,
and clinical features associated with dementia with LBs,
including extrapyramidal signs and visual hallucina-
tions, were assessed at each study visit. Logistic regres-
sion analyses determined whether patients who had LBs
were more likely than those without LBs to express spe-
cific clinical signs during follow-up. Cox analyses deter-
mined whether patients with LBs developed clinical signs
or died earlier. Generalized estimating equations were used
to compare rates of cognitive or functional change.
Results: Nineteen of the 51 patients had at least 1 LB in
one of the studied regions. In no case was a significant
relation noted between LBs and the presence of a mea-
sured clinical sign. No LB measure was associated with
an increased risk of developing any of the evaluated clini-
cal signs earlier in the disease. There was no association
between the presence of LBs and more rapid mortality
or more rapid disease progression.
Conclusions: In patients diagnosed as having AD
during life, we did not observe a relation of LBs noted
during postmortem examination with the presence of
any clinical feature that we assessed or with the rapidity
of disease progression. The relation between LBs and
specific clinical manifestations may be tenuous in these
patients.
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A S MANY AS one third to halfof patients diagnosed ashaving Alzheimer disease(AD) have concomitantLewy bodies (LBs) when
examined at autopsy. Several studies have
asked whether, in patients who meet clini-
cal and pathologic criteria for AD, there
are unique or additional clinical features
associated with the presence of LBs.1-9 The
clinical features of interest are those that
have been associated with dementia with
Lewy bodies (DLB), including extrapyra-
midal signs (EPS) and psychiatric fea-
tures (especially visual hallucinations).10
The findings to date have been inconsis-
tent. The present study was designed to
address this issue, using patients from the
Predictors Study.11
The Predictors Study was designed to
study the natural history of patients who
meet clinical criteria for probable AD.
These patients were followed up prospec-
tively with semiannual visits for up to 9.9
years before their death, and clinical fea-
tures were recorded at each visit. None of
the patients in the Predictors Study could
be clinically diagnosed as having DLB to
the exclusion of AD. However, many had
some of the clinical manifestations asso-
ciated with DLB, including visual hallu-
cinations and EPS. At autopsy, semiquan-
titative ratings for LBs were obtained in 4
brain regions. The present analyses deter-
mined whether those who had LBs were
more likely than those without to exhibit
some of the clinical features that have been
associated with DLB.
RESULTS
CLINICAL SEVERITY AT ENTRY
AND FREQUENCY OF LBs
Most patients had mild disease severity at
the intake visit; CDR was rated as mild in
84.3% (Table 1) and the mMMSE score
averaged 36.9 of 57. Table 2 summa-
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rizes the frequency of observed LBs in the studied re-
gions of interest. Nineteen of the 51 patients had at least
one LB in one of the studied regions. Demographic and
clinical features of the patients at the intake visit were
compared in patients who did and did not have LBs. At
the initial visit, there was no significant difference be-
tween the groups in age, mMMSE score, BDRS score, edu-
cation, or frequency of patients with an APOE e4 allele.
Patients with LBs were more likely to be male (x2=8.1,
P,.01). There was a trend for the patients with LBs to
have a longer duration of illness at the initial study visit
than those without LBs (t=1.8, P,.09) and for them to
have a CDR of mild vs moderate dementia severity
(x2=2.5, P,.12).
RELATION OF LBs TO CLINICAL
MANIFESTATIONS
Table 3 summarizes the frequency of the occurrence
of specific clinical features in patients with and without
LBs. The relation between the presence of LBs and spe-
cific clinical features of the disease was explored using
cross-tabulation, the x2 statistic, and logistic regression
analyses. Clinical features were considered to have been
present if they were expressed at any point during pa-
tient follow-up. The presence or absence of any LBs, the
presence or absence of LBs in each sampled area, and the
semiquantitative ratings for LBs in each sampled area were
all considered in separate analyses. In each case, sepa-
rate analyses explored the potential relation between LBs
and each of the clinical signs listed in Table 1. Fol-
low-up logistic regression analyses controlled for sex or
duration of illness. In no case was a significant relation
between LBs and the presence of a clinical sign noted.
RELATION OF LBs TO RISK OF EXPRESSION OF
CLINICAL SIGNS AND MORTALITY
Cox proportional hazard analyses were conducted to
determine if the presence of LBs at postmortem exami-
nation was associated with an increased risk of express-
ing a clinical sign during the disease or an increased
SUBJECTS AND METHODS
SUBJECTS
The Predictors Study cohort consists of 236 patients with
probable AD recruited at 3 sites: Columbia University Col-
lege of Physicians and Surgeons, New York, NY, The Johns
Hopkins University School of Medicine, Baltimore, Md, and
Massachusetts General Hospital, Boston. Inclusion and ex-
clusion criteria, recruitment methods, and the full evalua-
tion methods have been described previously.11 All patients
met National Institute of Neurological Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association cri-
teria for probable AD,12 except that clinically silent, small
subcortical lesions were allowed. To ensure that severity of
dementia was mild at study entry, all patients were re-
quired to have a modified Mini-Mental State Examination
(mMMSE)13 score of 30 or above (corresponding to approxi-
mately 16 on the standard MMSE). To ensure accurate ini-
tial assessment of psychotic symptoms, all patients were re-
quired to have not been taking neuroleptic medications for
at least 1 month before their initial evaluation.
We attempted to follow up all subjects semiannually
until they died. At the time of these analyses, 130 patients
had died; autopsies were obtained for 61 of them. Final neu-
ropathologic diagnoses are available from 57 autopsies. In
52 (91%) of these 57 cases, the diagnosis of AD was con-
firmed at autopsy. Two additional cases had senile changes
consistent with AD that were not sufficient for the diag-
nosis of AD (eg, focal tangles). Of the remaining 3 pa-
tients, 2 had hippocampal sclerosis and 1 had Creutzfeldt-
Jacob disease. Of the 52 patients diagnosed as having AD
at postmortem examination, material for this pathologic
evaluation study was available for 51.
Thus, 51 patients were included in the present study.
These patients were members of the Predictors Study cohort
who underwent autopsy, who were diagnosed as having AD
at postmortem examination, and for whom sufficient post-
mortem material was available for these pathologic studies.
CLINICAL FEATURES
The following clinical features were assessed at each 6-month
visit from the initial study visit until death.
Extrapyramidal Signs
Selected items from the Unified Parkinson’s Disease Rat-
ing Scale14 were used to rate extrapyramidal motor signs.
Hypophonia, masked facies, resting tremor, rigidity (neck
and each limb), bradykinesia or hypokinesia, and posture
and gait abnormalities were rated as absent, slight, mild-
moderate, marked, or severe (see Richards et al15 for com-
plete form). In addition to evaluating individual motor signs,
the presence or absence of EPS in general was considered.
Patients who had at least 1 sign rated mild-moderate or
worse were considered to have EPS, since ratings of this
severity are relatively more reliable and are likely to be noted
by the average clinician.15 Our analyses focused on both
drug- and non–drug-induced EPS. If, at the visit when they
were first detected, the patient was currently taking or had
ever taken medications that could induce EPS, then the signs
were considered to be drug induced. Otherwise, they were
considered non–drug induced, even if at subsequent visits
the patient received medications that could induce EPS.
Myoclonus
The presence of myoclonus was also assessed as part of the
neurological evaluation and through a structured clinical
history.
Psychosis
A semistructured interview, the Columbia University Scale
forPsychopathology inAlzheimer’sDisease,16 wasused toelicit
information about delusions, hallucinations, and other spe-
cific behavioral signs and mental states that occurred the
month before assessment. Specific delusions queried in-
cluded paranoid delusions, delusions of abandonment,
Continued on next page
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risk of expressing the sign earlier. No LB measure was
associated with an increased risk of any of the evaluated
clinical signs. Follow-up analyses included duration of
illness as a covariate. Again, no LB measure was associ-
ated with an increased risk of any of the evaluated clini-
cal signs.
Using Cox analyses, there was no association be-
tween the presence of LBs and more rapid mortality.
RAPIDITY OF PROGRESSION
Generalized estimating equation analyses were applied
to the prospectively collected mMMSE scores. Separate
generalized estimating equation analyses were con-
ducted to assess the effect of the presence or absence of
LBs in each brain region. The analyses demonstrated a
significant decline in mMMSE scores over time of ap-
proximately 3.6 points per 6-month follow-up interval.
Across all analyses, there were no differences between
patients with and without LBs in mMMSE scores at the
initial evaluation (ie, no significant group effect) or in
the rate of change of mMMSE scores over time (ie, no
significant interaction effect). Similar analysis of the pro-
spectively collected BDRS scores showed no difference
between the groups at the initial visit and no group dif-
ferences in the rate of change over time. Thus, the rate
of cognitive and functional progression of the disease did
not differ across the 2 groups.
COMMENT
We attempted to determine if there was an association
between the presence of LBs in 4 selected brain regions
post mortem and clinical features noted in extensive fol-
low-up of the patients during life. We found that the pres-
ence of LBs was not related to increased frequency of EPS
in general or of any specific extrapyramidal motor sign,
psychosis or any specific psychotic feature, or myoclo-
nus. Similarly, we found no relation between LBs and in-
creased risk of developing any of these disease features.
Finally, we found no relation between LBs and more rapid
disease progression or mortality.
somatic delusions, and misidentifications. For the purpose
of the present analyses, a delusion was considered present
regardless of its frequency of expression or the patient’s ac-
ceptance of dissuasion. Visual, auditory, olfactory, and tac-
tile hallucinations and illusions were specifically queried.
Cognition
Cognitive function was examined using the mMMSE,13,17
which includes the standard MMSE,18 the Wechsler Adult
Intelligence Scale digit span subtest,19 and additional at-
tention and calculation, general knowledge, language, and
construction items. The maximum score on this test is 57.
Other measures were also obtained at each study visit,
including the Blessed Dementia Rating Scale (part 1)20
(BDRS) to assess functional capacity and the Clinical De-
mentia Rating (CDR) scale21 to rate the overall severity of
the dementia.
The apolipoprotein E (APOE) e genotypes were avail-
able for 32 of the patients. The APOE genotype was deter-
mined after isolating DNA from white blood cells and di-
gesting the DNA with HhaI. The method for APOE
genotyping by Hixson and Vernier22 was modified slightly.23
NEUROPATHOLOGIC EVALUATION
All cases considered herein met neuropathologic criteria
for AD using the Consortium to Establish a Registry for Alz-
heimer’s Disease criteria.24 In addition, the presence of LBs
was evaluated.
Lewy bodies in the substantia nigra were rated as pres-
ent or absent. We performed semiquantitative ratings of LBs
in 3 other brain regions. Paraffin sections of cingulate, in-
sular cortex, and hippocampus (parahippocampal cortex
at the level of the lateral geniculate nucleus) were cut 7-µm
thick and stained with an antibody to ubiquitin, using an
avidin-biotin peroxidase technique and microwaving (10
minutes at high, 10 minutes at defrost in citrate buffer, pH
6.0, for antigen retrieval). Three randomly selected 310
microscopic fields from each section were rated for
the presence of ubiquitin-reactive inclusions, using the fol-
lowing scale: absent, 1 to 5 per field, 6 to 10 per field, or
more than 10 per field. The mean of the 3 ratings was used
as a quantitative measure of LB pathologic findings. For some
analyses, LBs were also rated as present or absent in each
brain region.
STATISTICAL ANALYSES
The intent of the analyses was to determine whether there
were differences in the clinical presentation of patients with
and without LBs. Both summary variables (such as EPS or
psychosis) and specific components of these summary vari-
ables (such as rigidity or hallucinations) were included in sepa-
rate analyses. The following clinical outcomes were evalu-
ated: thepresenceofnon–drug-induced,drug-induced,orboth
non–drug-induced and drug-induced EPS and specific mo-
tor signs, including tremor, rigidity, bradykinesia, gait dis-
order, or hypophonia; myoclonus; the presence of psy-
chotic features and specific features, including hallucination
(and, specifically, visual hallucinations), delusions, and il-
lusions; and mortality. The initial approach used cross-
tabulation and the x2 statistic to compare the frequency of
specific clinical signs at any point during follow-up in pa-
tients with and without LBs. Comparisons were conducted
for each region using both the semiquantitative ratings and
the present vs absent classification. In addition, patients with
and without any LBs in any region were compared. Fol-
low-up logistic regression analyses were used to control for
disparities in sex and duration of illness.
Cox analyses were used to determine whether the pres-
ence of LBs at postmortem examination was associated with
clinical signs emerging earlier in the disease. Cox analyses
were also used to evaluate potential differences in survival
among patients with and without LBs.
To determine whether the rate of decline differed in
patients with and without LBs, analysis of prospective change
in the mMMSE and BDRS scores was performed by apply-
ing generalized estimating equations to regression analy-
ses with repeated measures.25
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A major contribution of the present analyses lies in
the careful clinical follow-up that patients received. The
patients were studied prospectively, with semiannual ex-
aminations, for a mean±SD of 4.6±2.0 years. Clinical signs
of interest were ascertained and coded in a standardized
fashion at each study visit. This eliminates the potential
biases inherent in deriving clinical information from ret-
rospective chart reviews. Long-term follow-up of the pa-
tients also minimized the possibility that clinical signs
were not detected at a single clinical evaluation or de-
veloped after the clinical evaluation.
We also recognize several weaknesses to the analy-
ses presented herein. With regard to the pathologic stud-
ies, the semiquantitative analyses of LBs were limited to
a small number of brain regions and did not include any
regions of association cortex, and some brain samples were
unavailable for some of the patients. However, we ana-
lyzed the nigra and the paralimbic regions of the brain
that are among the most severely affected brain regions
in DLB. We also recognize that ubiquitin may not be as
sensitive or specific as a-synuclein immunostaining for
detecting LBs, and in principle neurofibrillary tangles
might be misidentified as LBs. However, quantitative
analyses in our laboratories have shown that the num-
ber of ubiquitin-positive LBs is virtually identical to the
number of a-synuclein–positive LBs,26 and experienced
investigators can differentiate LBs from neurofibrillary
tangles.
Some clinical features that have been associated with
DLB (eg, falls, syncope, or fluctuations in cognitive func-
tioning) were not formally assessed. It is possible that these
might have shown a stronger relation to the presence of
LBs.
It is important to stress that the present sample did
not include patients encompassing the full clinical spec-
trum of DLB. Rather, all of the patients in the present study
were diagnosed clinically as having AD, had to be mildly
impaired clinically, and had to not be taking neurolep-
tics for 1 month before the initial evaluation. All pa-
tients were evaluated initially for cognitive as opposed
to motor complaints. These data are most relevant to the
issue of whether variability in the clinical spectrum in
patients diagnosed clinically as having probable AD is a
function of LBs. The data herein do not provide infor-
mation about clinicopathologic relations in DLB.
Table 4 summarizes other studies that have com-
pared clinical features of patients with AD with and with-
out LBs. For many of the clinical features addressed in
these studies, the results are inconsistent. Compared with
those without LBs, patients with AD with LBs have been
reported to have more essential tremor and masked fa-
cies1; more severe rigidity,3 increased bradykinesia,
masked facies, shuffling gait, and rigidity4; and in-
creased frequency of 1 or more of a group of EPS.5,6 Two
studies2,7 besides our own found no differences in the fre-
quency of EPS, although the latter found more frequent
extrapyramidal side effects of neuroleptics.
It is notable that EPS were present in 32 subjects who
lacked LBs at autopsy. Another study evaluated EPS in
patients with AD who had no LBs and found that they
were associated with the number of neurofibrillary tangles
and neuropil threads in the substantia nigra.27 This sug-
gests that there can be multiple causes of EPS in AD, and
their presence does not necessarily indicate the pres-
ence of LBs. A recent study of diagnostic accuracy of de-
Table 1. Demographic and Clinical Variables at the Intake








mMMSE score, mean (SD) 36.9 (6.2) 36.7 (6.3) 37.3 (6.2)
BDRS score, mean (SD) 9.1 (3.8) 9.6 (4.2) 8.2 (2.9)
Age, mean (SD), y 73.2 (8.2) 73.0 (9.0) 73.6 (6.8)
Sex, No. (%) female 18 (35) 16 (50) 2 (10)†
Duration of illness, mean
(SD), y
4.4 (2.8) 3.9 (2.4) 5.3 (3.3)‡
Education, mean (SD), y 14.3 (3.1) 14.2 (3.1) 14.5 (3.1)
CDR at intake, No. (%)
Mild (1) 43 (84) 25 (78) 18 (95)
Moderate (2) 8 (16) 7 (22) 1 (5)
APOE, No. (%) with e4
allele (n = 32)
14 (44) 11 (50) 3 (30)
*mMMSE indicates modified Mini-Mental State Examination; BDRS, Blessed




Table 2. Number of Lewy Bodies
Noted at Postmortem Examination in 51 Patients*
Insula Cingulate Hippocampus Brainstem Any
Absent 32 32 37 30 32
Present 9 15 13 16 19
1-5 per 310 field 6 10 7 . . . . . .
6-10 per 310 field 3 3 4 . . . . . .
.10 per 310 field 0 2 2 . . . . . .
Unavailable 10 4 1 5 . . .
*Lewy bodies were considered to be present in any region if at least 1
per 310 field was noted. Semiquantitative counts were not done for the
brainstem. For each region, appropriate material was not available in some
cases. These are noted as unavailable. For the summary variables, Lewy bodies
were considered to be present if at least 1 Lewy body was present in 1 of the
included areas.
Table 3. Frequency of the Occurrence of Clinical Signs
at Any Time During Follow-up in Patients Without
and With Lewy Bodies (LBs) at Postmortem Examination
No. (%) of Patients
No LBs Any LBs
At least 1 extrapyramidal sign (mild-moderate
severity)
20 (87) 13 (87)
Rigidity 23 (88) 16 (94)
Hypophonia 12 (60) 10 (63)
Masked facies 14 (61) 12 (75)
Tremor 9 (35) 8 (47)
Bradykinesia 22 (85) 13 (81)
Gait 20 (83) 12 (80)
Any psychotic feature 27 (84) 16 (84)
Delusion 26 (81) 16 (84)
Hallucination 16 (50) 9 (47)
Illusion 9 (28) 5 (26)
Myoclonus 5 (16) 1 (5)
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mentia with LBs in 10 patients also found that of the 5
misdiagnosed patients 4 had AD with EPS.28
With regard to psychiatric symptoms, 2 studies2,7 re-
ported increased frequency of hallucinations, delu-
sions, and depression, and another4 reported increased
visual hallucinations only in AD with LBs. Two other stud-
ies1,3 besides our own reported no differences in psychi-
atric features.
Four studies3,6-8 besides our own noted no differ-
ence in dementia severity in patients with AD with and
without LBs. Another found that patients with AD with
LBs performed worse on delayed recall on a list learning
task but not on other memory measures or cognitive tests.5
One reported increased dementia severity.2 Three stud-
ies found different patterns of cognitive changes in the
face of equivalent overall dementia severity. One re-
ported that patients with AD with LBs had greater defi-
cits in attention, fluency, and visuospatial processing.1
A second found that patients with AD plus LBs per-
formed more poorly on tests of arithmetic, verbal flu-
ency, visuospatial processing, and psychomotor speed.4
The third found that patients with AD without LBs per-
formed more poorly on the memory subscale on the De-
mentia Rating Scale, whereas the AD plus LB group per-
formed more poorly on the initiation and perseveration
scale.9
Six studies1,3-5,7,8 besides our own noted no differ-
ences in rate of disease progression or survival between
patients with AD with and without LBs. One study2 re-
ported decreased survival time, and another6 reported both
an increased rate of cognitive decline and decreased sur-
vival time.
Several considerations affect the interpretation of
studies in this area and may account for some of the
variability in findings. Since LBs are just one of many
pathologic variables that may contribute to the clinical
picture, it may be important to evaluate clinical corre-
lates of LBs in the context of other pathologic indices,
particularly measures of amyloid burden and cell loss;
to date, this has not been done systematically. In addi-
tion, many studies, including the present one, exam-
ined brain tissue from a limited number of areas. Often,
Table 4. Summary of Articles Comparing Patients With Alzheimer Disease (AD) With and Without Lewy Bodies (LBs)*
Source, y AD
AD
and LBs Extrapyramidal Signs Psychiatric Symptoms Cognition Progression
Hansen et al,1
1990
9 9 › Essential tremor, masked
facies; fl limitation of
upward gaze





Equal rate of progression
McKeith et al,2
1992
37 21 No difference › Depression, visual and
auditory hallucinations,
delusions
› Dementia severity Fluctuations; fl survival


























58 24 No difference › Hallucinations and
delusions (caregiver reports);
› depression on Hamilton
Depression Rating Scale
Equal dementia severity Equal rate of
progression, equal
age at onset and
duration of illness
(n for AD = 55)
Samuel et al,8
1997
12 12 No information No information Equal dementia severity Equal rate of
progression, equal
survival time from last




23 23 No information No information Matched for dementia severity







148 40 › Parkinsonian
symptoms at entry
No information No initial difference › Rate of cognitive
decline; possibly ›
mortality from entry;




74 27 › (At least 2
extrapyramidal signs);
› bradykinesia







*In all cases, upward arrow indicates increased frequency or higher scores in the patients with AD and LBs; downward arrow, decreased frequency or lower scores.
†Sample sizes for dementia severity, extrapyramidal signs, and cognition comparisons, respectively.
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only the presence or absence of LBs was coded. Finally,
the quality of the clinical information about patients
during their lifetime and the extent of clinical follow-up
are variable.
In patients with AD, we did not observe any rela-
tion between the presence or absence of LBs and any
clinical feature that we assessed. Despite the quality of
our clinical information, one possibility is that more
extensive neuropathologic analyses will be required to
observe these clinicopathologic relations. The contribu-
tion of the LB to the clinical phenotype may not be suf-
ficiently strong enough to be revealed in the presence of
concomitant AD. Alternately, the relation between LBs
and specific clinical manifestations may be tenuous
among patients with pathologically confirmed AD.
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